Citigroup Initiates 'Underperform' Rating on Annexon (NASDAQ: ANNX)

• Citigroup initiated an "Underperform" rating on Annexon (NASDAQ: ANNX), citing inherent risks despite the company's promising biopharmaceutical pipeline.
• Annexon is advancing treatments for neuroinflammatory diseases, including vonaprument for geographic atrophy and tanruprubart for Guillain-Barré syndrome, with key trial data and regulatory submissions anticipated.
• The stock currently trades at $5.57, with a market capitalization of approximately $666.14 million, reflecting market skepticism despite its clinical progress.

On July 21, 2026, Citigroup initiates coverage on Annexon (NASDAQ: ANNX), assigning it an "Underperform" rating. This rating suggests the bank believes the stock may not perform as well as the broader market. At the time of the announcement, the stock price for Annexon is $5.57 per share.

Annexon is a biopharmaceutical company that develops treatments for neuroinflammatory diseases. These are conditions where the nervous system is damaged by inflammation. The company's work focuses on creating new therapies for diseases that affect nearly 10 million people around the world, making its research significant for a large patient population.

The company's pipeline includes vonaprument, a treatment for geographic atrophy (GA), a form of age-related vision loss. Annexon is presenting findings from its Phase 2 trial at the ASRS Annual Scientific Meeting. Data from the upcoming Phase 3 trial is expected in the fourth quarter of 2026, which is a key event for investors.

Another key therapy is tanruprubart for Guillain-Barré syndrome (GBS). As highlighted by Seeking Alpha, this treatment showed a 2.4-fold improvement over a placebo in Phase 3 trials. The company has submitted an application to European regulators and plans to file with the U.S. FDA in 2026, indicating progress toward market approval.

Despite this potential, the "Underperform" rating reflects the inherent risks. The stock currently trades at $5.57, with a market capitalization of approximately $666.14 million. Market capitalization is the total market value of a company's outstanding shares. The stock's 52-week range is between a low of $2.03 and a high of $7.18.